Amplia Therapeutics Limited (ATX.AX)
AUD 0.05
(0.0%)
AUD 0.05
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 8.43 Million AUD | 13.97% |
| 2023 | 7.4 Million AUD | 31.62% |
| 2022 | 5.62 Million AUD | 45.15% |
| 2021 | 3.87 Million AUD | 71.56% |
| 2020 | 2.25 Million AUD | 17.33% |
| 2019 | 1.92 Million AUD | -59.95% |
| 2018 | 4.8 Million AUD | -46.2% |
| 2017 | 8.93 Million AUD | 32.47% |
| 2016 | 6.74 Million AUD | 24.2% |
| 2015 | 5.42 Million AUD | 32.8% |
| 2014 | 4.08 Million AUD | 58.47% |
| 2013 | 2.57 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 8.93 Million AUD | 20.73% |
| 2024 Q2 | 3.56 Million AUD | 0.0% |
| 2024 Q4 | 5.01 Million AUD | 0.0% |
| 2023 Q4 | 2.75 Million AUD | 0.0% |
| 2023 FY | 7.4 Million AUD | 31.62% |
| 2023 Q2 | 4.64 Million AUD | 0.0% |
| 2022 Q4 | 3.54 Million AUD | 0.0% |
| 2022 Q2 | 2.08 Million AUD | 0.0% |
| 2022 FY | 5.62 Million AUD | 45.15% |
| 2021 Q4 | 2.44 Million AUD | 0.0% |
| 2021 FY | 3.87 Million AUD | 71.56% |
| 2021 Q2 | 1.42 Million AUD | 0.0% |
| 2020 Q4 | 1.36 Million AUD | 0.0% |
| 2020 Q2 | 888.53 Thousand AUD | 0.0% |
| 2020 FY | 2.25 Million AUD | 17.33% |
| 2019 Q2 | 701.04 Thousand AUD | 0.0% |
| 2019 Q4 | 1.08 Million AUD | 0.0% |
| 2019 FY | 1.92 Million AUD | -59.95% |
| 2018 FY | 4.8 Million AUD | -46.2% |
| 2018 Q4 | 1.71 Million AUD | 0.0% |
| 2018 Q2 | 3.08 Million AUD | 0.0% |
| 2017 FY | 8.93 Million AUD | 32.47% |
| 2017 Q2 | 4.54 Million AUD | 0.0% |
| 2017 Q4 | 4.18 Million AUD | 0.0% |
| 2016 FY | 6.74 Million AUD | 24.2% |
| 2016 Q4 | 4.17 Million AUD | 0.0% |
| 2016 Q2 | 2.85 Million AUD | 0.0% |
| 2015 Q3 | 59.49 Thousand AUD | -96.96% |
| 2015 Q2 | 1.95 Million AUD | 3469.46% |
| 2015 Q1 | 54.79 Thousand AUD | 0.0% |
| 2015 FY | 5.42 Million AUD | 32.8% |
| 2015 Q4 | 3.2 Million AUD | 5285.59% |
| 2014 Q3 | 54.79 Thousand AUD | 0.0% |
| 2014 Q1 | - AUD | 0.0% |
| 2014 Q4 | 54.79 Thousand AUD | 0.0% |
| 2014 FY | 4.08 Million AUD | 58.47% |
| 2014 Q2 | - AUD | 0.0% |
| 2013 FY | 2.57 Million AUD | 0.0% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acrux Limited | 8.55 Million AUD | 1.337% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | 57.325% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 85.018% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 73.046% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 74.2% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -2719.163% |
| AdAlta Limited | 6.76 Million AUD | -24.614% |
| Alterity Therapeutics Limited | 23.4 Million AUD | 63.96% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -1301.702% |
| BTC Health Limited | -1.03 Million AUD | 911.965% |
| CSL Limited | 7.56 Billion AUD | 99.888% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 78.684% |
| Hexima Limited | 1 Million AUD | -736.255% |
| Immutep Limited | 42.87 Million AUD | 80.325% |
| Memphasys Limited | 3.67 Million AUD | -129.332% |
| Noxopharm Limited | 7 Million AUD | -20.507% |
| Prescient Therapeutics Limited | 10.89 Million AUD | 22.599% |
| Race Oncology Limited | 14.77 Million AUD | 42.888% |
| Starpharma Holdings Limited | 22.81 Million AUD | 63.027% |
| Tissue Repair Ltd | 6.66 Million AUD | -26.533% |
| Biotron Limited | 5.11 Million AUD | -65.061% |
| Biome Australia Limited | 7.91 Million AUD | -6.63% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -1087.767% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -205.53% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -41.812% |
| Patrys Limited | 4.93 Million AUD | -70.995% |
| Orthocell Limited | 15.36 Million AUD | 45.114% |
| Imugene Limited | 135.09 Million AUD | 93.756% |
| PYC Therapeutics Limited | 60.91 Million AUD | 86.152% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -845.557% |
| Cynata Therapeutics Limited | 11.12 Million AUD | 24.163% |
| Arovella Therapeutics Limited | 10.78 Million AUD | 21.785% |
| Nanollose Limited | 12.5 Thousand AUD | -67380.394% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -152.123% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -329.251% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -104.485% |
| Nyrada Inc. | 4.55 Million AUD | -85.19% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 96.867% |
| Dimerix Limited | 25.64 Million AUD | 67.104% |
| PharmAust Limited | 6.65 Million AUD | -26.72% |
| AnteoTech Limited | 12.18 Million AUD | 30.781% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 87.043% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | 61.098% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -85.588% |
| Actinogen Medical Limited | 22.77 Million AUD | 62.953% |
| Immuron Limited | 9.13 Million AUD | 7.684% |
| Argenica Therapeutics Limited | 8.26 Million AUD | -2.015% |